<DOC>
	<DOCNO>NCT01641783</DOCNO>
	<brief_summary>Gastric cancer remain one major cause cancer death around world , especially Asia . For advanced gastric cancer , even treat chemotherapy , prognosis still poor , investigator urgently need effective strategy treat advance gastric cancer , however , recommend First-line chemotherapy advance gastric cancer . Taxane promise gastric cancer . Nanoparticle Albumin-Bound ( Nab ) Paclitaxel ( Abraxane，ABI-007 ) high effectiveness low toxicity approve breast cancer first-line chemotherapy many country . The investigator initiate prospective phase II clinical trial Nab-Paclitaxel plus Capecitabine first-line treatment advance gastric cancer observe efficacy safety .</brief_summary>
	<brief_title>Efficacy Safety Study ABI-007 Plus Capecitabine First-line Chemotherapy Advanced Gastric Cancer Patients</brief_title>
	<detailed_description>A single arm , open , phase II study Nab-Paclitaxel plus Capecitabine first-line treatment advance gastric cancer . Nab-Paclitaxel give intravenously day 1 8 dose follow . Treatment repeat every 3 week : Nab-Paclitaxel:125 mg/m2 ; Capecitabine give orally twice day follow 14 consecutive day , follow 1-week rest . Treatment repeat every 3 week . Capecitabine:1000mg/m2 , twice daily ( bid ) . If applicable , value response prognosis predictive factor expect identified .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>sign informed consent form ; histologically cytologically confirm gastric cancer ; Age 1875 year ; Advanced recurrent , metastatic disease ; Performance Status Eastern Cooperative Oncology Group ( ECOG ) 02 ; Life expectancy least 12 week ; At least one measurable disease ( accord RECIST , Response Evaluation Criteria Solid Tumors ) ; prior history chemotherapy beyond 6 month end systemic adjuvant treatment ; Haematopoietic status : Absolute neutrophil count &gt; 1.5 x 109/L ; Platelet count &gt; 90 x 109/L ; Hemoglobin least 90g/l ; Hepatic status : Bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; AST ALT ≤ 2.5 time ULN ( liver metastasis ) , ≤ 5 time ULN ( liver metastasis ) ; ALP ≤ 2.5 time ULN ( liver metastasis ) , ≤5 time ULN ( liver bone metastasis ) ; serum albumin ≥ 30g/L ; Renal status : Creatinine ≤ 1.5 time ULN calculate creatinine clearance , use CockcroftGault formula , ≥ 40 mL/min ; Able swallow retain oral medication ; peripheral neuropathy grade 2 great ; symptomatic brain metastasis ; know history uncontrolled symptomatic angina ; clinically significant arrhythmia , congestive heart failure , uncontrolled hypertension ( ≥ 180/110 ) , unstable diabetes mellitus , dyspnea rest , chronic therapy oxygen ; dementia , alter mental status , psychiatric condition would prevent understand render ICF ; active uncontrolled infection ; pregnant lactating woman ; dysmetabolism nanoparticle Albuminbound paclitaxel Capecitabine unable swallow retain oral medication , intestinal Obstruction , alimentary tract hemorrhage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>advanced</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>capecitabine</keyword>
	<keyword>first line therapy</keyword>
</DOC>